

Index

- AAAT, *see* anionic amino acid transporter
- AADC, *see* aromatic amino acid decarboxylase
- AAT, *see* amino acid transporter
- A β , *see* amyloid β
- ablation, 326, 329
thermal, 329
- absorption, 17, 43, 48, 57, 60, 110, 164, 234
high, 54, 325
improved, 49
improved oral, 234
nasal, 42
opsonin, 238
poor, 113
rapid, 81, 239
- accumulation, 15, 22–23, 60, 113, 115, 125, 138, 177, 195–96, 260, 265, 294, 321, 414, 439
edelfosin, 110
enhanced, 275
increased, 327
intracellular, 20
major, 414
radioactivity, 414
siRNA/Chitosan-PEGBrain, 296
tumour, 190, 193–94, 204, 239
- active pharmaceutical ingredient (API), 212, 217, 221–22, 224–25, 230–35
- acute hypersensitivity reaction, 119
- acute ischaemic events, 463
- acute ischaemic stroke (AIS), 412
- acute lymphocytic leukaemia, 266
- acute myeloid leukaemia, 266
- adenosine triphosphate (ATP), 17, 323, 418
- administration, 52–54, 79–81, 85, 88, 90, 93–94, 105–7, 109–14, 118–21, 123–34, 211–16, 239–40, 354–57, 429, 461–62
direct intracranial, 273
efficient phenytoin, 21
home, 41
intracerebral, 266
intrathecal, 384
nasal, 44, 49, 58, 239, 434
parenteral, 172, 218, 237
peripheral, 41
single, 268
stereotactic, 300
systemic, 41, 58, 79–80, 112, 272, 295, 458
- adsorption, 4, 109, 237, 294, 444
electrostatic, 87, 121
selective protein, 237
- adsorptive-mediated transcytosis (AMT), 14, 82–83, 90, 97–99, 107–8, 115, 126, 129, 290–91, 295–97
- aggregation, 92–93, 137, 166, 169, 199, 228–29, 265, 292, 319, 321, 325, 438, 443
particle, 458
- AIS, *see* acute ischaemic stroke
- Alzheimer's disease (AD), 23, 40, 61, 76, 91, 106, 128, 190, 197–98, 265, 274, 276, 408, 415, 444, 459, 462–63
- amino acid transporter (AAT), 84
- AMLs, *see* aqueous magnetoliposomes
- amorphous nanostructures, 225

- amphiphiles, 88, 102
- AMT, *see* adsorptive-mediated transcytosis
- amyloid β (A β), 87, 92–94, 122–24, 134–35, 174, 198, 415
- anionic amino acid transporter (AAAT), 84
- ANNs, *see* artificial neural networks
- antibodies, 4, 191–92, 200–201, 264, 290, 292, 295, 331, 337, 392–94, 440
- antitransferrin monoclonal, 335
- epidermal growth factor receptor monoclonal, 332
- high-affinity, 327
- low-affinity, 327
- monoclonal, 91, 135, 294
- monoclonal melanotransferrin, 107
- monovalent bispecific, 327
- primary, 395
- single domain, 195
- anticancer activity, 443
- anti-ischaemic activity, 96
- antioxidant, 22, 95–96, 100, 108, 113, 199–200, 336
- natural, 100
- antipsychotic agents, 106, 110
- antipsychotic drug, 217
- antiretroviral drug, 415–16
- antisense oligonucleotides (ASOs), 259–61, 264, 266–67, 270
- antisolvent, 224–25, 227–28, 234–35, 239
- supercritical, 221–22, 227
- antisolvent-to-solvent ratio, 234
- antitumour activity, 109, 127, 197, 427
- API, *see* active pharmaceutical ingredient
- ApoB, 267, 295
- ApoE, 91–92, 109, 125, 135, 295
- apolipoproteins, 91–92, 135, 176, 199, 203, 238, 267, 294–95
- apoptosis, 22, 95, 135, 266, 297, 326, 330, 333–34, 415
- hyperthermia-induced, 334
- aptamers, 4, 259, 264–65, 292
- antimyelin DNA, 265
- artificial, 265
- brain-penetrating, 265
- chemically modified, 265
- therapeutic, 265
- AQP4, *see* aquaporin-4
- aqueous magnetoliposomes (AMLs), 334–36
- aquaporin-4 (AQP4), 16, 22
- aromatic amino acid decarboxylase (AADC), 23
- artificial neural networks (ANNs), 436, 439
- ASOs, *see* antisense oligonucleotides
- astrocytes, 12, 18, 22–23, 107, 137, 290, 323, 335, 384, 386, 389, 393–94, 396–97, 462
- ATP, *see* adenosine triphosphate
- AuNPs, 296
- AuNRs, 194, 328–29
- axonal transport, 46, 81
- intracellular, 44
- barriers, 9–10, 13, 82, 177, 192, 218, 289–91, 293, 299, 323, 384–85, 388, 393–95, 397–99, 433
- biological, 218, 432
- brain-tumour, 439
- cerebrospinal fluid, 9, 13, 323
- chemical, 384, 396
- dynamic cell-based protective, 431
- endothelial, 232
- functional, 45
- gel-based, 389
- kinetic, 231

- kinetic energy, 117
- leakier, 397
- major, 75
- mechanical, 399
- neuroprotective, 15
- physical, 386, 396
- physiological, 5, 105, 463
- protective, 12, 259
- restrictive single-layer, 299
- selective, 276
- selective permeability, 76
- tight, 389, 396
- Bayesian regularised neural network (BRNN), 435
- BBB, *see* blood–brain barrier
 - intact, 176
 - lipophilic, 217
 - normal, 176
 - tumour, 301
 - in vitro, 439
- BBB disruption, 24–25, 177, 290, 419
- BBB dysfunction, 22
- BBB integrity, 25, 163, 173, 323, 383
- BBB penetration, 102, 118, 139
- BBB permeability, 21–22, 99, 107, 134–35, 177–78, 192, 199, 323, 397, 419, 428–29, 431, 437–38, 445
- BBB permeation, 163, 428, 437–38
- BBTB, *see* blood–brain tumour barrier
- BC, *see* brain cancer
- BCECs, *see* brain capillary endothelial cells
- BCRP, *see* breast cancer resistance protein
- BCS, *see* biopharmaceutics classification system
- BCSFB, *see* blood–cerebrospinal fluid barrier 13–17, 323
- BECs, *see* brain endothelial cells
- binding, 14, 17, 107, 122, 174, 260–61, 267, 270, 292, 294–95, 298, 429, 439, 441, 444
 - cell, 458
 - cellular, 440
 - glioma-targeted, 99
 - leptin-derived peptide, 295
 - nonspecific, 321
 - plasma protein, 41, 43, 429
 - potential, 443
- bioaccumulation, 138, 331
- bioavailability, 41, 50, 81, 93, 95, 102–3, 106–7, 110–11, 113, 115, 127, 234–35, 240, 359, 365
- biocompartments, 54, 59
 - nontargeted, 57
- biocompatibility, 5, 78–79, 85–88, 102, 104, 107, 122, 137, 172, 196, 239, 321, 324, 331, 338
- biodegradability, 85–86, 104, 165, 321
 - drug, 62
- biodegradation, 76, 136–37, 139
- biodistribution, 105, 113, 120, 127, 172, 196, 267, 294–95, 358, 414, 417, 457
- bioimaging, 163, 458–59, 461
 - optical, 196
- biomarkers, 190, 198, 201–2, 204, 264
- biomolecules, 191, 200–201, 203–4, 429, 458
- bionanosystems, 322
- biopharmaceutics classification system (BCS), 217, 234, 239
- block copolymers, 100, 102, 228
- blood–brain barrier (BBB), 12–14, 16–25, 40–43, 76–77, 79–84, 103–5, 107–10, 118–35, 162–63, 172–79, 292–95, 335, 383–89, 394–401, 427–40, 459–63

- blood–brain tumour barrier (BBTB), 97–98, 411, 414
- blood–cerebrospinal fluid barrier (BCSFB), 13–17, 323
- blood circulation, 43, 80, 82, 110, 362, 383
 - systemic, 384
- blood–spinal cord barrier (BSCB), 259
- BMMs, *see* bone marrow–derived macrophages
- bone marrow–derived macrophages (BMMs), 416
- brain, 15–16, 20–25, 39–50, 52–62, 75–77, 79–84, 92–100, 104–31, 135–37, 234–40, 257–60, 268–70, 272–76, 298–302, 427–34
 - healthy, 137, 301
 - human, 393–95, 397, 409
 - infected, 397
 - ischaemic, 202
 - living, 440
 - living mammalian, 258
 - normal, 414
 - postischaemic, 135, 300
 - right, 414
- brain accumulation, 109, 139, 172, 298, 328
- brain barriers, 9–10, 40, 75–76, 97, 161–62, 212, 217, 236, 239, 289–90, 383–84, 387, 407–8, 427, 429–30
- brain/blood ratio, 111
- brain cancer (BC), 76, 90, 119, 190, 192–93, 195–96, 204, 328–29, 408
- brain capillaries, 16, 23, 97–98, 108, 265, 268, 294, 327, 399
- brain capillary endothelial cells (BCECs), 97–98, 108, 268, 294, 298–99, 301
- brain delivery, 76, 79, 84–85, 88, 90–92, 99, 102, 105, 111, 115, 123, 138–39, 290–96, 298–99, 303–4
 - clinical, 140
 - effective, 98
 - enhancing drug, 109
 - systemic, 298
 - therapeutic, 104
- brain diseases, 76, 105, 122, 140, 203–4, 258, 419
- brain disorders, 9, 189–90, 258, 264, 407–10, 412, 414, 416, 418, 420, 422, 424, 429
- brain distribution, 22, 59, 76, 239
- brain drug delivery, 4, 79, 90, 102–4, 122, 138, 161–62, 169, 191, 234, 259, 317, 320
- brain drugs, 54, 59, 111, 138
- brain endothelial cells (BECs), 10, 12–15, 18, 20, 22, 25, 115, 119, 172–73, 274, 276, 396–97
- brain gene delivery, 126
- brain microenvironment, 383
- brain nanodelivery systems, 431
- brain parenchyma, 9, 12–13, 16, 44–45, 88, 98, 107, 109, 290, 293, 298–300, 303, 327
- brain pathology, 76, 104, 257–58
- brain pathophysiology, 383
- brain/plasma ratio, 235
- brain structures, 60, 172, 337, 352, 409
- brain theranostics, 327, 331, 338
- brain therapeutics, 76
- brain therapy, 318–19, 337
- brain tissue, 43, 45, 49–50, 54–56, 59, 93, 96, 108–9, 114, 177, 294, 383–84, 386, 396, 400
 - acidic inflamed, 138
 - healthy, 303
 - human, 85, 89
 - mouse, 114
 - normal, 301

- postmortem, 94
- rat, 55
- brain-to-plasma ratio, total, 10, 12, 42
- brain tumour, 125–28, 134, 175, 190, 192, 195, 197, 272, 274, 276, 409–15, 418–19, 429, 441–42, 454–55
 - aggressive, 411, 454, 461
 - human, 410, 412
 - metastatic, 414
 - orthotopic, 269
- brain uptake, 42, 82, 104, 118, 121–22, 236, 294, 298
- breast cancer resistance protein (BCRP), 10, 14, 17–20, 22–23, 394
- BRNN, *see* Bayesian regularised neural network
- Brownian relaxation, 167, 330
- Brust–Schiffrin method, 169
- BSCB, *see* blood–spinal cord barrier
- CAAT, *see* cationic amino acid transporter
- cancer, 5, 60, 97, 112, 213, 264, 266, 318, 320, 324, 442, 458–60
 - advanced, 461
 - breast, 336
 - early-stage, 459
 - prostate, 266
- cancer cells, 5, 17, 135, 196, 323–24, 329–30, 391, 398
- carbon-based vehicle, 356
- carbon nanotubes, 78, 198, 320–21, 438
- cargo, 4, 86, 162, 179, 292, 298, 417
- carrier-mediated transcytosis (CMT), 82, 84, 290–91
- carrier-mediated transport, 290, 298
- carriers, 4, 92, 139, 162–63, 167, 177, 237, 270, 274–75, 291, 296, 430–31, 443–44
 - amino acid, 298
 - colloidal, 162
 - lipid-based, 274
 - micellar drug, 102
 - nanostructured lipid, 78, 103, 111, 275, 432
 - new drug, 439
 - nonviral, 303
 - nose-to-brain, 114
 - novel lipid, 274
 - particulate drug, 440
 - promising targeted, 430
 - single, 79
- cationic amino acid transporter (CAAT), 84
- cationic carriers, 292
- cationic liposomes, 90–91, 98–99, 270–72, 292, 299, 418
- CED, *see* convention enhanced delivery
- cell death, 178, 266, 300, 326, 328, 335, 408, 415, 442
- cell-penetrating peptides (CPPs), 83, 172, 272, 276, 353, 371, 373, 375, 377
- cell uptake, 261, 268–69
- central nervous system (CNS), 9–17, 39–44, 46–49, 52–54, 56–61, 265–66, 268, 289–90, 319, 351–52, 383–84, 396–97, 407–8, 431, 459–63
- cerebral hypoperfusion, 98
 - chronic, 22
- cerebral ischaemia, 76, 95, 192–93, 202–3, 412
- cerebral ischaemia/reperfusion (CIR), 76, 95–96, 139
- cerebral oedema, 96
- cerebral palsy, 416

- cerebrospinal fluid (CSF), 13–17, 24, 40, 43–47, 50–51, 54–55, 57–58, 113, 201, 299–300, 414, 429, 463
- cerebrovascular accident, 408
- chemotherapeutic agents, 107, 194, 196, 418, 460
- chemotherapeutic drugs, 192, 276, 317, 319, 460
- chemotherapy, 167, 178, 193–94, 330, 415, 440
 - conventional, 319
- chitosan, 62, 81, 100, 116, 195, 276
- Chol, *see* cholesterol
- cholesterol (Chol), 89, 91–98, 267–69, 271, , 273–75, 376
- Chol-siRNA conjugates, 267–69
- choroid plexus, 9–10, 13, 15–16, 323
- CIR, *see* cerebral ischaemia/reperfusion
- circulation, 4, 80, 103, 275, 321, 388
 - cerebral, 21
 - short, 110
 - systemic, 16, 42–43, 45, 57–58, 299
 - systemic venous, 15
- circulation time, 76, 292
 - prolonged, 96, 267
- clearance, 16, 51, 81, 107, 138, 140, 292, 364
 - decreased brain, 24
 - early NC, 80
 - mucocilliary, 114
 - reduced, 120
 - reduced renal, 331
 - retarded quercetin, 111
- clinical trials, 19, 61, 76, 139, 204, 258, 290, 333, 408–9, 413, 455–56
 - human, 385, 461
- CMAs, *see* critical material attributes
- CMC, *see* critical micellar concentration
- CMT, *see* carrier-mediated transcytosis
- CNS, *see* central nervous system
- CNS diseases, 11, 25, 41, 61, 85, 103, 118, 122, 409, 419
- CNS disorders, 11, 25, 259, 303–4, 384–85, 400, 408, 410, 413–15
- CNS drug delivery, 5, 50, 298
- CNS penetration, 10, 20, 42
- CNS-to-blood concentration ratio, 57
- coatings, 80–81, 97, 109, 114, 165, 177, 276, 433
- colloidal stability, 79, 166, 170–72, 177, 271, 358
- combinative technology (CT), 229, 322, 419
- conjugation, 108, 122, 174, 203, 266–68, 275, 324
 - covalent, 87, 121
 - direct, 270
- convention enhanced delivery (CED), 441, 461
- core
 - inorganic, 190–92, 195, 198
 - nanocrystal, 238
- CPPs, *see* cell-penetrating peptides
- CQAs, *see* critical quality attributes
- CRISPR-Cas9, 258
- critical material attributes (CMAs), 353, 371, 373, 375
- critical micellar concentration (CMC), 86, 102
- critical quality attributes (CQAs), 353, 355, 357, 364–73, 375–77
- CRM, *see* curcumin
- CSF, *see* cerebrospinal fluid
 - artificial, 55
 - human, 49
 - impaired, 24
- CT, *see* combinative technology

- curcumin (CRM), 93–94, 113, 123, 198, 444
- cytotoxicity, 107, 109, 113, 134, 138, 175, 199, 269, 391
- DCS, *see* developability
 - classification system
- DDIs, *see* drug–drug interactions
- decision trees (DTs), 435, 437
- decomposition, 168, 170–71, 176
- deep learning (DL), 428, 436–37
- deep learning networks (DLNs), 436–37
- degradation, 86, 103, 118, 136–37, 223, 260, 263, 265, 328, 333, 357, 360, 366, 370, 373–74
 - chemical, 86, 104
 - direct, 261
 - enzymatic, 43, 90, 335
 - high, 88
 - physical, 441
 - plasma protease, 43
 - premature, 303
 - rapid, 276, 295
 - targeted protein, 276
- delivery, 24–25, 42–43, 52–54, 98–99, 112–13, 118, 161–63, 271–72, 276, 289–94, 298–99, 431–35, 441–42, 458–59, 461–62
 - brain-targeted, 108
 - brain-targeted therapeutic, 106
 - cellular, 270
 - combined lethal-7a miRNA, 334
 - controlled, 321
 - convection-enhanced, 300, 331
 - direct, 46, 60
 - effective, 13, 60
 - efficient, 48, 81, 108, 162, 289
 - enhanced, 178
 - fast, 356
 - glioma-directed, 301
 - glioma-targeted, 99
 - image-guided, 175
 - intracerebral, 430
 - intravenous, 55, 57
 - localised, 320
 - local NC, 80
 - magnetic-guided, 338
 - material, 441
 - nanocrystal BBB, 237
 - nasal, 59, 81
 - nonviral, 290
 - prompt, 202
 - rapid, 44
 - receptor-mediated, 300
 - safe, 266
 - selective, 267
 - systemic, 41, 43, 262
 - targeted, 192, 266, 301, 320, 430, 438, 459
 - targeted intratumoural, 301
 - targeted nanoparticle, 296
 - transdermal, 99–100
- delivery systems, 417, 429, 431, 444
 - brain drug, 97, 427–28
 - efficient drug, 63, 458
 - nanotherapeutic brain, 428
 - nonviral nucleic acid, 289, 291, 303
 - novel nasal drug, 48
 - pharmacologic NP, 416
 - self-double-emulsion drug, 78, 117
- dementia, 22, 60, 459
 - parkinsonian, 201
 - virus-associated, 416
- dendrimers, 87, 121–22, 131, 135, 138, 294, 320–21, 416, 431
 - anionic, 122
 - biodegradable, 138
 - carbosilane, 122
 - naked cationic, 135
 - new biosafe, 138
 - polyester, 138
- density functional theory (DFT), 444

- deposition, 52–53, 61, 92–93, 100, 109
 - blood-mediated brain drug, 57
 - irregular, 60
- depression, 23–24, 60–61, 113
 - refractory, 63
 - respiratory, 19
- design of experiment (DoE), 371, 373, 375–77
- destruction, 115
 - fast photochemical, 327
 - magnetic-mechanical, 334
 - ultrasound-targeted microbubble, 331
- developability classification system (DCS), 217
- DFT, *see* density functional theory
- diagnosis, 5, 163, 190–92, 197–98, 201–2, 259, 265, 320, 322, 407, 417, 438, 455, 458–62
 - early, 197, 459
 - pre-symptomatic, 203
 - sensitive, 321
 - simultaneous, 191
 - targeted, 202
- differential scanning calorimetry, 232, 235
- diffusion, 16, 45, 50, 88, 219, 293, 329, 399, 428–29, 433, 440–41
 - convection-enhanced, 293
 - free, 290
 - limited, 299
 - passive, 44, 76–77, 82, 84, 119, 217–18, 435
 - poor, 303
- dilution, 86, 356, 362
 - systemic, 43
- direct transport, 47, 50, 57–58
- direct transport percentage (DTP), 58–59
- diseases, 11–12, 22, 24, 60–61, 76–77, 123–31, 133–34, 189–91, 197, 258, 317–19, 400–401, 407–11, 417, 459–60
 - active, 417
 - autoimmune, 264
 - brain-associated, 105
 - brain-related, 162, 191, 427, 445
 - cardiovascular, 60, 92
 - common intracerebral, 41
 - human, 140, 408, 455
 - ischaemic, 192
 - lysosomal storage, 351
 - metabolic, 135
 - neurological, 24, 260, 290, 408–9, 461
 - refractory central, 63
 - stable, 461
- disorders, 11, 383, 407–11, 459
 - bipolar, 112, 233
 - brain-related, 189–92, 204–5
 - fatal, 457
 - major depressive, 113
 - neuropsychiatric, 232
 - psychotic, 104, 110
- dispersion, 117, 223
 - coarse, 371
 - colloidal, 103, 117
 - stable, 116
- dissolution, 103, 122, 203, 211–12, 217–20, 230, 232–33, 240
 - complete, 212
 - solid drug, 219
- distribution, 16–17, 44, 52–53, 59–60, 112, 126, 298–99, 303, 358, 364, 374, 430, 432, 439, 442
 - differential, 13
 - homogenous, 59
 - intrabrain, 12
 - local, 300
 - near-instantaneous, 293
 - nonspecific, 458
 - particle, 373, 465
 - preferential, 40
 - relative, 57
 - systemic, 57

- DL, *see* deep learning
- DLNs, *see* deep learning networks
- DMD, *see* Duchenne muscular dystrophy
- DNA, 126, 135, 195, 201, 265–66, 273, 276, 292, 299, 328, 330, 333–34, 418
 - double-stranded, 201
 - intact, 260
 - modified single-stranded, 260
- DoE, *see* design of experiment
- doses, 11, 40, 52, 81, 96, 110, 112, 236, 269, 419, 461
 - clinical, 20
 - effective radiation, 334
 - high radiation, 327
 - inhaled, 442
 - injected, 135
 - low, 108
 - minimum, 106
 - multiple, 80
 - oral, 41, 113
 - therapeutic, 20
- double-stranded RNA (dsRNA), 262, 264, 266
- downregulation, 13, 23, 460
- DOX, *see* doxorubicin
- doxorubicin (DOX), 98, 108, 127, 134–35, 175, 194, 222, 297, 328, 335, 337, 394, 414–15, 440–41, 461
- drug absorption, 49, 114, 218
- drug accumulation, 77, 102, 238, 328, 330, 430, 461
- drug administration, 41, 52, 54, 56, 212, 232, 273, 291, 319, 391
- drug bioavailability, 54, 106, 356–57
- drug brain delivery, 211
- drug carriers, 105, 429, 454–55, 464
- drug concentrations, 12, 16, 40, 42, 45, 54–55, 59–60, 112, 224, 234, 360, 376–77
- drug delivery, 4–5, 16, 24–25, 61–63, 101–2, 121–22, 162–63, 352, 356, 418, 428, 430, 432, 439–41, 463–65
 - antiretroviral, 416
 - brain-targeted, 303
 - chemotherapeutic, 454, 461
 - direct intranasal, 43
 - direct nose-to-brain, 442
 - efficient, 10, 59
 - enhanced, 116
 - intranasal, 25
 - intranasal brain, 54, 239
 - nanoparticle-mediated, 428, 431
 - nasal, 48
 - oral brain, 232
 - systemic, 41
 - targeted, 165, 458, 460
- drug distribution, 24, 55, 59, 416, 429
- drug–drug interactions (DDIs), 19–20
- drug formulation, 12, 43, 52–53, 56
- drug loading, 86–87, 102, 104, 112, 163, 223, 235, 358, 466
 - active, 371
 - high, 239–40
 - significant, 79
- drug nanocrystals, 211, 217, 221, 240
- drug penetration, 18, 323
- drug permeability, 361, 368, 391, 427, 432, 436
- drug permeation, 431, 435, 437
- drug products, 354–58, 360, 362, 364–65
 - complex, 353, 378
 - implanted, 355
 - nanocrystal, 217, 224
- drug release, 77, 85–86, 89, 112, 138, 336, 338, 354, 358, 364, 369, 441, 444–45, 460, 466
 - controlled, 111

- local, 417
- sustained, 199
- tuneable, 444
- drug resistance, 17–18
- drugs, 10–12, 15–17, 19–20,
 - 39–41, 43–49, 52–62, 76–77,
 - 79–82, 109–16, 119–35,
 - 227–29, 237–40, 391–92,
 - 438–41, 443–46
- acidic, 228
- active, 56, 463
- amorphous, 212
- anticancer, 439
- antiepileptic, 17, 24
- antiplatelet, 202
- antipsychotic, 106, 233
- antiretroviral, 20, 416
- biological, 290
- central, 40, 60–61
- charged, 463
- commercialised, 385
- conventional, 258, 430
- covalently bound, 335
- cytotoxic, 190, 193
- free, 106, 111, 114, 121, 360, 377
- hydrophilic, 88
- hydrophobic, 88, 227–28
- hydrophobic model, 445
- lipophilic, 79, 217
- liposomal, 414
- low-aqueous-solubility
 - chemotherapeutic, 238
- low-molecular-weight, 319
- neuroprotective, 202
- new, 76, 391, 457, 462
- non-encapsulated, 203
- nontargeted, 440
- nose-to-brain, 57
- novel, 400
- parent, 56, 237
- polymeric fluoropyrimidine, 266
- siRNA, 291
- small-molecule, 25, 271
- solid, 211
- solubilised, 218
- soluble, 240
- stable, 458
- systemic circulating, 76
- target, 77
- targeted chemotherapeutic, 461
- targeted chemotherapy, 440
- tested, 408
- therapeutic, 321
- unconjugated, 174
- unencapsulated, 371
- victim, 20
- water-soluble, 103, 218, 232, 237
- drug substance (DS), 44, 354, 359–60, 365–67
- drug-targeting efficiency (DTE), 58–59, 235
- drug transport, 54, 57, 81, 118, 400, 428, 439–40
- drug uptake, 59, 218, 440
- DS, *see* drug substance
- dsRNA, *see* double-stranded RNA
- DTE, *see* drug-targeting efficiency
- DTP, *see* direct transport
 - percentage
- DTs, *see* decision trees
- Duchenne muscular dystrophy (DMD), 258, 262
- dysfunction, 123–24, 384
 - cerebrovascular, 24
 - intrinsic brain, 409
 - neuronal, 268
 - synaptic, 197
- EAE, *see* experimental allergic encephalomyelitis
- ECF, *see* extracellular fluid
- ECM, *see* extracellular matrix
- EE, *see* encapsulating efficiency
- effectiveness, 192, 200, 333, 397

- efficacy, 105, 107–8, 112–13, 197, 199, 204–5, 355, 364–66, 398, 400, 409, 412–14, 428–30, 442–43, 461
- antitumour, 177
- desired, 359
- improved, 19
- limited, 105
- neuroprotective, 409
- efficiency
 - brain-targeting, 110, 238
 - higher, 131
 - peak olfactory deposition, 442
 - transmigration, 338
 - treatment, 234
- efflux, 10–11, 14–15, 17, 20, 109, 119–20, 323, 352, 394
- efflux transporters, 10, 12–14, 17, 19, 21, 25, 107, 237, 385
- EGFR, *see* epidermal growth factor receptor
- EMA, *see* European Medicines Agency
- encapsulating efficiency (EE), 110, 112–15, 119–20
- encapsulation, 77, 85–86, 88, 90, 95, 109, 111, 113, 171, 270, 272, 274–75, 292, 359–60, 376–77
- endocytosis, 44, 104–5, 107, 109, 131, 177, 212, 327–28, 431, 439, 463
- adsorptive, 44
- clathrin-mediated
 - energydependent, 123
 - receptor-mediated, 176, 324
 - receptor-mediated absorptive, 323
- endothelial cells, 5, 98, 104, 108, 172–74, 176, 323, 384–86, 388–89, 393, 395–99, 433, 438, 460, 462
- endotoxins, 362, 369
- environment, 5, 75, 325
- biological, 139
- constant magnetic, 322
- host, 439
- human, 386
- physiological, 97
- regulatory, 464
- surrounding, 326
- enzymes, 15, 19, 81, 108, 115, 129, 260, 263, 270, 385, 396, 444
- drug-metabolising, 15
- high-MW, 129
- lysosomal, 135
- EP, *see* European Pharmacopeia
- epidermal growth factor receptor (EGFR), 301, 332, 461
- epilepsy, 18, 23–24, 40, 60, 62, 112, 351, 384
- pharmacoresistant, 24
- refractory, 17, 63
- epithelial cells, 9, 13–15, 17, 299
- EPR, enhanced permeability and retention 97, 319, 322
- EPS, *see* extrapyramidal symptoms
- ethosomes, 78, 85, 88, 99–100
- European Medicines Agency (EMA), 212–14, 357
- European Pharmacopeia (EP), 355, 365
- excipients, 86, 104, 212, 359–60, 438
- exocytosis, 14, 172, 439
- exosomes, 5, 274, 295, 431
- experimental allergic
 - encephalomyelitis (EAE), 105–6
- exposure, 12, 20, 137, 337, 360, 395
- foetal, 22
- patient, 366
- preferential, 59
- sertraline, 21
- short-term, 21
- extracellular fluid (ECF), 429

- extracellular matrix, 12, 24, 384, 389, 397, 400, 439
- extrapyramidal symptoms (EPS), 106–7, 110
- FA, *see* fractional anisotropy
- FDA, *see* Food and Drug Administration
- failure mode and effects analysis (FMEA), 371–73
- first-pass metabolism, 111, 239
 - hepatic, 106, 113
 - intense, 108
- fluid flow, 387, 390, 400, 441
- fluids, 9, 12–13, 15, 62, 89–90, 167, 227, 385–86, 395, 399, 439–41
 - biological, 276
 - computationally simulated, 442
 - diamagnetic, 167
 - extracellular, 388, 429
 - interstitial, 12, 16
 - physiological, 275
 - simulated gastrointestinal, 93
 - supercritical, 225
 - surrounding, 167
- fluorescence resonance energy transfer (FRET), 236, 325
- FMEA, *see* failure mode and effects analysis
- focused ultrasound (FU), 98, 299, 329, 417, 440
- Food and Drug Administration (FDA), 193, 212–16, 231, 237, 258, 291, 299, 333, 357, 369
- formulations, 47–48, 53–54, 59, 61, 91, 94, 123–34, 190, 192, 194–97, 218, 357, 359, 364–71, 443
 - classical, 81
 - commercial, 119, 234
 - cRGD-directed, 194
 - lipid, 272
 - lipid-based, 136
 - liposomal, 91, 94–96, 101, 136, 272
 - liver-targeted, 291
 - nanomicellar, 197
 - nanoparticle, 443
 - potential, 257
 - therapeutic, 81, 90
 - traditional, 218
- Förster resonance energy transfer, 325
- fractional anisotropy (FA), 134–35, 200
- free radicals, 23, 93, 95, 334
- freeze-drying, 222, 225, 227, 229
- FRET, *see* fluorescence resonance energy transfer
- Freundlich equation, 218
- FU, *see* focused ultrasound
- functionalisation, 78–79, 92, 162, 169, 177, 199, 204, 275, 338, 429–30
 - chemical, 163
 - click chemistry, 138
- functionality, 17–18, 179, 323, 328
- gamma scintigraphy, 56, 111
- GB, *see* glioblastoma
- GBM, *see* glioblastoma multiforme
- GDNF, *see* glial cell-derived neurotrophic factor
- generally recognised as safe (GRAS), 86, 104, 136–37
- gene delivery, 259, 290, 328, 458
 - clinical, 289, 291, 303
 - targeted, 195
- gene expression, 131, 196, 258, 260, 262, 269, 272, 296, 298, 412
- genes, 131–33, 270, 273–76, 296–97, 319, 398, 411
 - mammalian, 409
 - pathological, 258
 - reporter, 131, 135, 418

- gene silencing, 261, 268–69, 291, 300
- gene therapeutics, 304
- gene therapy, 87, 122, 290, 303
- genome, 258
- human, 257–58
 - mouse, 409
- GFP, *see* green fluorescent protein
- glial cell-derived neurotrophic factor (GDNF), 94–95
- glioblastoma (GB), 109, 113, 125, 135, 175, 194–96, 275, 301, 331, 391–92, 398, 408, 411, 414–15, 418, 438, 461
- glioblastoma multiforme (GBM), 107–8, 130, 135, 175, 177–78, 192, 195, 265–66, 319, 322, 392, 460–61
- gliomas, 97–99, 102–3, 107, 109–10, 119, 122, 128, 193–97, 271–72, 290, 295–97, 300–301, 319, 443, 460–61
- glioma therapy, 178, 302, 331, 339
- malignant, 318
- GNPs, *see* gold nanoparticles 324, 326–28, 330, 334, 337
- gold nanoparticles (GNPs), 199, 201, 203, 324, 326–28, 330, 334, 337, 417
- gold nanorods, 163, 175, 194, 328
- GRAS, *see* generally recognised as safe
- green fluorescent protein (GFP), 195–96, 273, 296
- growth factor receptors, 83, 265
- epidermal, 301, 461
 - platelet-derived, 397
 - vascular endothelial, 323
- growth factors, 46, 397, 414
- epidermal, 332
 - nerve, 201, 203, 415
- growth inhibition, 134, 194, 297
- HBMECs, *see* human brain microvascular endothelial cells
- HD, *see* high dose
- HD, *see* Huntington's disease
- HDL, *see* high-density lipoprotein
- health, 25, 61, 369, 457, 465
- global, 258, 457
 - human, 407–8
- heat shock protein (HSP), 333
- helper lipids, 90, 271, 273
- HGAP, *see* high-gravity antisolvent precipitation
- HGRP, *see* high-gravity reactive precipitation
- high-density lipoprotein (HDL), 267–68, 270
- high dose (HD), 76, 219, 329, 408, 410
- high-gravity antisolvent precipitation (HGAP), 221, 227
- high-gravity precipitation, 227
- high-gravity reactive precipitation (HGRP), 221, 227–28
- high-pressure homogenisation (HPH), 117, 119, 222–23, 229, 231–32, 234, 238–39
- high-speed homogenisation, 120, 371
- high-throughput screening, 217, 386
- HIV, *see* human immunodeficiency virus
- HNs, *see* hybrid nanosystems
- HPH, *see* high-pressure homogenisation
- HPLC, *see* high-performance liquid chromatography
- HSP, *see* heat shock protein
- human brain microvascular endothelial cells (HBMECs), 107, 335, 396, 399
- human immunodeficiency virus (HIV), 18, 83, 120, 135, 337–39, 415–17, 463

- human umbilical vein endothelial cells (HUVECs), 196, 396–97
- Huntington's disease (HD), 76, 265, 408
- HUVECs, *see* human umbilical vein endothelial cells
- hybrid nanosystems (HNs), 4, 91, 189–206, 208, 210
- hybrid NCs, 79, 96–97
- hybrid NPs, 199–201, 203–4
- hydrogels, 292, 322, 328, 331, 389, 392
- hydrophilic, 13, 79–80, 85–87, 100–102, 115, 121, 134, 171, 228, 271, 276, 292, 352, 463
- hydrophobic, 82, 84–88, 100–103, 111, 121, 134, 170, 260, 266–67, 271, 274, 322, 438, 445
- hydrophobicity, 269, 432
- hypertension, 23–25
- hyperthermia, 79, 165, 175, 178–79, 326, 330, 333, 336–38
 - photoinduced, 320
- hypoxia, 24, 271, 459
- imaging, 56, 190, 192–94, 196, 199, 202–4, 317, 321–22, 326–27, 330, 388–89, 392–93, 417, 419, 428
 - diagnostic, 197
 - enhanced magnetic particle, 337
 - fluorescence, 194, 199
 - magnetic resonance acoustic radiation force impulse, 440
 - optical, 196, 321, 325, 417
 - optical hypoxia, 459
 - optic hypoxic, 459
 - real-time high-resolution, 390
 - simultaneous, 190, 193
 - targeted, 202
 - in vivo bioluminescent, 418
- immune cells, 397, 460
- immune response, 269, 416
- immune system, 80, 216, 292, 458
- impairment, 95, 383
 - cerebral blood flow, 24
 - neurological, 135
- INCs, *see* inorganic nanocarriers
- inflammation, 17, 93, 115, 135, 137, 216, 300, 395
 - early brain, 203
 - local, 138
- inhibitors, 19, 23, 106, 119, 264, 394
 - antiretroviral protease, 120
 - balanced dual reuptake, 113
 - first-generation, 19
 - glutamate release, 105
 - pDNA encoding, 301
 - peptide aggregation, 87
 - small-molecule, 135
 - third-generation, 19
 - third-generation P-gp, 19
 - tyrosine kinase, 18
- injections, 80, 128, 132, 175, 269, 294, 299–300, 328, 355, 369, 414, 442
 - direct, 300
 - ethanol, 371
 - intra-arterial, 98
 - intracerebral, 413
 - intracerebroventricular, 41
 - intracranial, 293, 299, 301
 - intradermal, 275
 - intramuscular, 237
 - intraatrial, 268
 - intrathecal, 259, 299
 - intraventricular, 96
 - local, 303
 - micelle, 298
 - preoperative, 327
 - systemic, 175, 289, 293, 298, 300–301
- inorganic nanocarriers (INCs), 77–79, 136, 164
- inorganic nanomaterials, 78, 190–91, 193, 198–201, 203

- inorganic nanoparticles, 162–63, 165, 167, 172, 179, 320, 431
 - bare, 172
 - undecorated, 172
- instability, 85, 109, 111, 229, 231
 - chemical, 113
 - physical, 230
 - thermodynamic, 231
- interactions, 19, 92, 99, 135, 139, 235, 237, 385, 388–89, 428–29, 433, 439, 443–45, 458, 460
 - cell, 295, 389, 458, 464
 - complex, 430
 - effective, 432
 - electrostatic, 82, 90, 92, 97, 108, 292
 - environmental, 409
 - hydrogen-bonding, 260
 - intermolecular, 219
 - nanoparticle-membrane, 432
 - neuronal, 138
 - noncovalent, 84
 - nonspecific, 292
 - nonspecific protein, 275
 - partial covalent, 444
 - pharmacokinetic, 19
 - physiological, 386
 - staging, 84
 - synergistic, 92
 - tissue, 179
 - unknown tissue, 4
 - unpredictable, 137
 - unpredictable biological, 140
 - unspecific, 291–92
- internalisation, 4, 14, 237, 272, 297–98, 415
 - axonal drug, 46
 - cellular, 131, 237
- interstitial fluid (ISF), 16–17, 24
- intracranial delivery, 299
- intranasal administration, 5, 39–40, 42–43, 47, 52, 55, 57–62, 81, 239, 259, 434
- intranasal delivery, 39, 41, 54–56, 59–60, 62, 239, 430
- intranasal route, 5, 40–41, 50, 63, 240
- intraperitoneal administration, 200
- intraperitoneal injection, 201
- intrathecal injections/infusions, 39
- intravenous administration, 5, 42, 55, 57, 59–60, 172, 175, 230, 273, 302, 356
- intravenous infusion, 238
- intravenous injection, 40–42, 47, 55, 58, 259, 267, 301, 369
- IONPs, *see* iron oxide nanoparticles
- iron oxide nanoparticles (IONPs), 165–66, 195, 197, 332
- ISF, *see* interstitial fluid
- junctions, 323, 352
 - dysfunctional, 460
- Juran Trilogy, 353
- knockdown, 270, 273–74, 297, 328–29
- Kunitz domain, 134
- large unilamellar vesicles (LUVs), 88–89
- laser, 175, 194, 329
- LD, *see* low dose
- LDL, *see* low-density lipoprotein
- LDL receptors (LDLRs), 83, 86, 92, 109, 119, 298
- LDLR-related protein (LRP), 83, 135, 295, 300, 332
- LDLRs, *see* LDL receptors
- lesions, 411
 - early atherosclerotic, 459
 - focal ischaemic, 413
 - induced, 132
 - kainic acid-mediated, 300
 - metastatic, 414

- ligands, 20, 82, 84, 91, 97, 107–8, 120, 122–34, 171–72, 290, 292, 323, 325, 330–31, 335
 - active, 333
 - donor, 325
 - endogenous, 172, 298
 - nanoparticles-surface, 431
 - organic, 198
 - targeting, 103, 108, 272, 274, 294
 - tumour-targeting, 460
 - withdrawing, 325
- lipid-based nanocarriers, 86, 266
- lipid-based nanoparticles, 259, 275, 292
- lipid bilayers, 88–89, 335, 369, 432
- lipid micelles (LMs), 128, 135
- lipid nanoparticles, 86, 103–4, 110–11, 114, 136, 263, 371
 - drug-loaded, 110
 - hybrid polymeric, 114
 - neutral, 275
- lipids, 82, 85–86, 88–91, 96–97, 99–104, 108, 135–37, 266–68, 270–71, 274, 365, 373, 377, 431, 433
 - amphiphilic, 102
 - cationic, 90, 271, 275
 - constitutive, 271
 - functional, 103
 - hybrid, 267
 - neutral, 271
 - physiological, 86, 104
 - responsive, 85
 - synthetic amino, 273
- lipophilic, 76, 101, 104, 118, 217, 266–67, 270, 275, 352
- lipophilicity, 12, 40, 90, 110
- lipoplexes, 90, 99, 292
- liposomes, 78, 85–86, 88–98, 101–2, 270–73, 295, 299–300, 320–21, 328, 331, 334–35, 364, 371–74, 376–77, 441
 - anionic, 98
 - baicalein-loaded, 93
 - brain-targeted, 24
 - ceramide-PEGylated, 273
 - charged, 92, 98
 - classic, 99
 - CRM-conjugated, 93
 - ideal, 272
 - ionisable, 271
 - mApoE-PA, 92–93
 - natural compound-loaded, 96
 - neutral, 98
 - pH-responsive, 271
 - quercetin-loaded, 94
 - thermosensitive, 336
 - vectorised, 202
- liquid lipids, 103, 111–15, 275
- LMs, *see* lipid micelles
- LNA, *see* locked nucleic acid
- localised surface plasmon resonance (LSPR), 163–65, 175
- locked nucleic acid (LNA), 261–62, 264, 270, 272
- low-density lipoprotein (LDL), 83–84, 109, 176, 267, 295, 332
- low dose (LD), 110, 329
- LRP, *see* LDLR-related protein
- LSPR, *see* localised surface plasmon resonance
- LUVs, *see* large unilamellar vesicles
- lyophilisation, 227, 275, 356
- Machado–Joseph disease (MJD), 272
- macromolecules, 16, 41, 83, 100, 271, 323, 396, 419
 - therapeutic, 25
- macrophages, 5, 80, 118, 237, 397
- macrospheres, 410, 413
- magnetic hyperthermia, 162, 165, 167, 178, 317, 330, 332, 334, 338, 442
- magnetic iron oxide nanoparticles, 162, 167, 170

- magnetic iron oxides, 161, 168, 170, 173, 179
- magnetic nanoliposomes, 200
- magnetic nanoparticles (MNPs), 162, 165–68, 170, 173, 177–78, 200, 317–18, 320, 322, 324, 326, 328, 330–36, 338, 340, 342, 442–43
- magnetic nanosystems, 178
- magnetic particle imaging (MPI), 337
- magnetic properties, 165, 171, 190, 193, 199, 331
- magnetic resonance imaging (MRI), 162, 165, 175, 177, 195–98, 200, 203, 321–22, 327, 331–32, 416–17, 419, 440, 442, 459
 - nuclear, 321
- magnetisation, 165–66, 330
- magnetite nanoparticles, 165–66, 170–71, 177–78, 332
- magnetoliposomes, 318, 320, 322, 331, 334–39
- major depressive disorder (MDD), 113
- MAR, *see* motional averaging regime
- matrix, 99, 212, 240, 328, 444–45
 - collagen, 389
 - organic, 200
 - polymeric core, 116
 - risk estimation, 371, 374
 - solid, 103
- MCC, *see* mucociliary clearance
 - nasal, 62
 - rapid, 52
- MDD, *see* major depressive disorder
- medical devices, 456, 464–66
 - active implantable, 464
 - biological evaluation of, 465–66
 - diagnostic, 464
 - nanomaterial-based, 465
- medicines, 41, 85, 383, 456, 464
 - conventional, 320
 - modern, 197
 - new biological, 303
 - traditional, 324
- messenger RNA (mRNA), 19, 258, 260–61, 263, 268–70, 274, 295, 300
- metabolism, 48, 92, 441, 462
 - balanced cerebral, 15
 - first-pass hepatic, 110
 - first-pass liver, 81
 - pH-mediated, 108
 - rapid, 113, 392
- micelles, 4, 86, 100, 102–3, 125, 134, 197, 202, 272–73, 298, 320–21, 334, 431
 - IONP, 197
 - lipidic, 78
 - PIC, 298
 - polymer, 292
- microemulsions, 62, 85, 116–17, 171
- microenvironments, 13, 386, 388, 390–92, 398, 441
 - cerebral, 391
- microfluidic BBB models, 388, 390–91, 396
- microfluidic devices, 397–98, 400
- microfluidics, 387, 390, 394, 401
 - hydrogel, 392
- microfluidic systems, 384, 386–88, 390, 393
- microRNA, 4, 263–65, 267, 333
 - artificial, 263
 - disease-causing, 264
 - endogenous, 264
 - mature, 264
 - synthetic, 264
- microsphere, 410, 413
- microvessels, 18, 293, 389, 393
- MJD, *see* Machado–Joseph disease
- MNPs, *see* magnetic nanoparticles

- modified red blood cell membrane-coated nanocrystals (MRBC-CNCs), 238
- mononuclear phagocytic system (MPS), 129, 135, 212, 237
- motional averaging regime (MAR), 322
- MPI, *see* magnetic particle imaging
- MPS, *see* mononuclear phagocytic system
- MRBC-CNCs, *see* modified red blood cell membrane-coated nanocrystals
- MRI, *see* magnetic resonance imaging
 - dynamic contrast-enhanced, 419
 - gadolinium-based, 440
 - intraoperative, 327
- mRNA, *see* messenger RNA
 - chemically modified, 291
 - complementary, 263
- MRP, *see* multidrug resistance-associated protein
- MS, *see* multiple sclerosis
- mucociliary clearance, 43, 48, 53–54, 81, 239
- multidrug resistance-associated protein (MRP), 14–15, 107, 394
- multiple sclerosis (MS), 11, 23, 40, 76, 265, 290, 319, 408, 416, 430
- multiwall carbon nanotubes (MWCNTs), 415
- mutations, 319
 - animal, 411
 - gene, 410
 - genetic, 411
 - genotypic, 396
- MWCNTs, *see* multiwall carbon nanotubes
- NAAT, *see* neutral amino acid transporter
- nanocarriers (NCs), 4–5, 80–83, 91, 96–97, 189–90, 238, 258, 294, 351–52, 354–56, 358–60, 362, 364, 366–72, 374–78, 380, 382, 427–30, 433–34, 463
 - biocompatible, 139
 - biomimetic, 238
 - brain-penetrating, 170
 - effective drug delivery, 4
 - glucosylated, 298
 - gold-based, 161
 - hybrid, 199
 - inorganic, 77–78, 168
 - efficient, 93
 - lipid-based, 82
 - most prevalent, 90–91
 - nucleic acid-loaded, 90
 - octadecyl-quaternised
 - carboxymethyl chitosan, 193
 - polymeric, 86–87
 - soft-matter, 89
 - targeted, 24–25
 - theranostic albumin, 203
 - unique multifunctional, 191
- nanoclusters, 330, 445
- nanocrystals (NCs), 211–12, 215, 217–18, 220–21, 223–25, 227, 229–40, 462
- nanoemulsions, 78, 85, 87, 116–20, 356
- nanoflowers, 163
- nanoformulation, 194
- nanogels, 356, 431
- nanoheaters, 178
- nanoliposomes, 200
- nanomaterials, 5, 204, 318, 320–21, 431, 462, 464–66
 - carbon-based, 77
 - hybrid, 205
- nanomedicines, 73, 77, 197, 212, 257, 317–20, 415, 455, 459, 465–66

- nanoparticles (NPs), 103, 109,
 - 113–15, 161–65, 167–77,
 - 189–90, 192, 194, 196,
 - 198–99, 201, 203–4, 218–19,
 - 294–95, 298, 324–27, 332–35,
 - 417, 419, 429–34, 438–44,
 - 453–55, 457–64
- anionic, 115
- azide-containing lipo-oligomer
 - core, 293
- biocompatible, 318
- bioresponsive carrier, 292
- camouflaged, 5
- carbon, 461
- cationic, 115
- chitosan, 295
- composite, 177
- curcumin, 415
- decorated, 295
- ferrite, 331
- functionalised hydrogel, 444
- gelatine, 328
- glucose-decorated, 298
- gold, 162–63, 168, 173, 294,
 - 324, 433
- gold-based, 338
- hybrid, 116
- hydrophobic iron oxide, 171
- lactoferrin-conjugated PEG-
 - PLGA, 415
- large, 298
- maghemite, 444
- magnetic and plasmonic,
 - 161–62, 317
- magnetoelectric, 333
- metal, 164
- metallic, 321
- micelle-/liposome-like, 459
- monodispersed, 171
- mucoadhesive, 114
- multifunctional, 189–90
- organically modified silica, 299
- paclitaxel-containing, 461
- plasmonic and magnetic, 320
- polycyanoacrylate, 116
- polymer, 116
- polystyrene, 294
- positively charged, 229, 292
- siRNA, 301
- siRNA-containing HD5, 329
- solid co-solvent, 227
- solid lipid matrix, 4
- spheroidal, 169
- superparamagnetic, 166, 178,
 - 433
- superparamagnetic Fe₃O₄, 170
- targeted, 328
- tempol-loaded PLGA, 415
- ultrasmall, 333
- nanoparticle uptake, 327, 331, 439
- nanoplatfoms, 174, 179
 - hybrid, 202–3
- nanoprobe, 195
- nanorods, 165, 175, 328
- nanospheres, 164
 - hollow, 165
 - peptide-functionalised hollow
 - gold, 163
 - transferrin-targeted, 416
- nanostars, 163–64
- nanostuctured lipid carriers
 - (NLCs), 78, 85, 103–4, 111–15,
 - 136, 275–76, 432
- nanostuctures, 87, 191, 463
 - anisotropic gold, 175
 - nonpolymeric, 462
- nanosuspensions, 212, 223,
 - 230–31, 233–34, 237–40, 416
- nanosystems, 61–62, 161–62,
 - 323–24, 328–29, 336–38,
 - 427–28, 430, 432, 434, 436,
 - 438, 440, 442, 458–59, 462–63
- graphene-based, 78
- intranasal carrier, 62
- lipid-based, 85
- polymer-based, 292
- potential, 339
- promising, 335

- recent, 318
- recent plasmonic/magnetic generation, 320
- single, 334
- smart, 4
- nanotechnology, 4–6, 202–3, 318, 352–53, 378, 408, 414, 416–17, 436, 454–55, 458–59, 462, 464–66
- nanotheranostics, 5, 317–18, 320–38, 340, 342, 344, 346
- nanotherapy, 136, 445–46, 458
- nanotriangles, 165
- nanovectors, 195–96
- nasal cavity, 5, 40, 42–48, 50–54, 56–58, 61–62, 81, 114–15, 276, 356
- nasal delivery, 49
- nasal drug absorption kinetics, 48
- nasal mucosa, 42, 45, 48–50, 53–54, 61–62, 81–82, 110, 114–15
- nasal sprays, 52, 356, 363, 366
- ncRNA, *see* noncoding RNA 258, 264
- NCs, *see* nanocarriers
- NCs, *see* nanocrystals
- NDs, *see* neurodegenerative disorders
- near infrared (NIR), 93, 163–65, 175
- Néel relaxation, 167, 330
- neoplasms, 192
 - malignant, 457
- neovascular tumour, 323
- neural networks, 435–36
 - artificial, 436
 - deep, 436
 - genetic, 435
- neuroblastoma, 92, 264
- neurodegeneration, 92, 408
- neurodegenerative diseases, 76, 87, 90, 93–94, 102, 105, 124, 163, 174, 264–65, 319–20, 409–10, 457, 459
- neurodegenerative disorders (NDs), 60, 192–93, 197, 199, 201, 204, 409–11, 414, 419, 443
- neuroinflammation, 24, 93, 118, 140, 416
 - post-stroke, 203
- neurological conditions, 258, 384
 - chronic, 81
- neurological disorders, 40–41, 60, 95, 258, 261, 274, 290, 303, 351, 407–8, 410, 413, 454–55, 458, 462
 - genetic, 397
- neurological pathologies, 85
 - molecular, 413
- neuronal cells, 135, 175, 257, 266, 273, 300
- neurons, 12, 16, 18, 93–94, 123–24, 132, 135–37, 268, 272–73, 384, 386, 389, 396–97, 410, 437
 - cerebral, 200
 - dopamine-generating, 94
 - dopaminergic, 140, 411
 - nondopaminergic, 411
 - primary, 268–69
 - sensitive, 137
 - sensory, 44
 - substantia nigra dopamine, 94
- neuroprotection, 93, 123, 197, 199, 203, 415–16
- neuroprotective effects, 25, 93, 95, 106, 124, 128, 198–200
- neurotoxic, 22, 92, 139, 259
- neurotoxicity, 137–38, 140, 179, 199
- neurotoxins, 23, 411
- neurotransmitters, 15, 93, 398
- neutral amino acid transporter (NAAT), 84
- NIR, *see* near infrared
- NLCs, *see* nanostructured lipid carriers

- anionic, 115
- cationic, 115
- fluorescent-dye-loaded, 114
- keto-loaded, 114
- lipid matrix of, 103, 113
- noncoding RNA (ncRNA), 258, 264
- nose-to-brain delivery, 40, 43, 60–62, 110, 115, 429
- nose-to-brain drug delivery, 41, 43, 45, 49–50, 52, 54, 62, 434
- nose-to-brain pathway, 47–49
- nose-to-brain transfer, 45, 55
- nose-to-brain transport, 40, 43, 49, 55, 60
- nose-to-CSF transport, 50
- Noyes–Whitney equation, 219
- NPs, *see* nanoparticles
 - acid-modified selenium, 199
 - α -synuclein, 201
 - carbohydrate-functionalised, 203
 - cRGD-directed, 194
 - dextran iron-oxide, 203
 - diagnostic, 419
 - empty, 419
 - gold plasmonic shell, 198
 - hybrid silica, 199
 - magnetic-fluorescent Fe_2O_3 , 198
 - magnetic paclitaxel, 193
 - negative, 442
 - polymeric, 194
 - siRNA/PLGA, 297
 - superparamagnetic, 201
- nucleation, 168–69, 171, 224
 - homogeneous, 224
 - uniform, 227
- nucleic acid formulations, 295, 299, 303–4
 - nonviral, 292, 303
- nucleic acid nanoparticles, 303
- nucleic acids, 90, 99, 122, 260, 262, 271–75, 289–92, 295, 303, 328–29, 431
 - bicyclic locked, 261–62
 - charged, 271, 275
 - chemically modified, 289
 - large, 290, 292
 - therapeutic, 289–91, 303
- ODNs, *see* oligonucleotides
 - antiproliferative, 259
 - conformationally constrained, 262
 - negatively charged, 259, 267
 - preneutralised, 275
 - ssRNA, 264
 - steric blocking, 259
- off-target distribution, 24, 140
- olfactory bulbs, 40, 42, 44, 46, 55–56, 59–60, 114
- olfactory epithelium, 5, 44, 50, 52, 54, 61, 82
- olfactory route, 50, 56, 442
- oligomers, 92, 128, 201, 261–62, 293, 301
- oligonucleotides (ODNs), 257–64, 266–67, 270–72, 274–77, 290
 - antisense, 259
 - synthetic, 257
 - therapeutic, 258
- ONCs, *see* organic nanocarriers
 - lipid, 136–37
 - lipid-based, 103, 136, 138
 - non-lipid-based, 85
 - nose-to-brain, 110
 - off-targeted, 137
 - polymeric, 89, 138
 - potential, 90
 - promising, 117, 122
 - safe, 137
- oral administration, 57, 80, 106, 110–11, 113, 218, 232, 259, 417, 460
- oral bioavailability, 110–11, 113, 217, 232, 234

- organic nanocarriers (ONCs),
 - 75–79, 81–82, 84–85, 89,
 - 91, 97, 102–5, 107, 111, 114,
 - 116–17, 120–34, 136–40
- Ostwald ripening, 117, 220, 229–30
- oxidative stress, 22, 93–95, 137, 199–200, 415–16
- PAMAM, *see* polyamidoamine
- Parkinson's disease (PD), 23–24, 61, 76, 94–95, 100, 124, 135, 139–40, 190, 197, 200–201, 204, 290, 294, 408, 410–11, 415
- particles, 164–67, 169–73, 211–12, 218–21, 223, 225, 227–30, 238–39, 322, 325–26, 354–55, 364, 373–74, 445, 462
- citrate-stabilised, 169
- crystalline, 171
- diameter, 225
- endogenous lipoprotein, 267
- frozen solid, 225
- iron oxide, 4
- large, 114, 167, 218, 230, 232
- layer-by-layer, 329
- multidomain, 168
- nanosized, 211
- natural LDL, 109
- negatively charged, 229
- seed, 170
- semiconductor, 196
- single-domain, 167
- smaller, 229–30, 294
- solid colloidal, 116
- spherical, 218, 224, 230
- subvisible, 355
- ultrasmall, 203
- pathology, 5, 9, 197, 258, 265, 408, 410
 - brain-related, 4
 - neurodegenerative, 190, 199
 - neurofibrillary tangle, 124
 - nonmotor, 408
 - vascular, 76
- pathways, 43–46, 52, 334, 385, 428
 - active penetration, 176
 - biochemical, 409
 - biodegradation/bioelimination, 79
 - direct, 5, 42
 - direct neurological, 55
 - direct nose-to-brain transport, 59
 - distinct transport, 59
 - dysfunctional cancer-related, 412
 - electrochemical, 168
 - endocytic, 135, 271
 - epithelial, 44, 46
 - exact transport, 56
 - excretory, 462
 - extracellular transport, 46
 - HSP-mediated, 333
 - indirect, 43
 - indirect vascular, 57
 - natural, 274
 - olfactory nerve, 44
 - signalling, 397
 - systemic, 43
 - trigeminal, 46, 58
- PD, *see* Parkinson's disease
- PDI, *see* polydispersity index
- pDNA, *see* plasmid DNA
 - therapeutic, 301
- PEG, *see* polyethylene glycol
- PEI, *see* polyethylenimine
- penetration, 45, 100, 111, 114–15, 165, 275, 297, 329, 414, 440
 - enhanced brain, 120
 - facile, 177
 - poor, 114
 - poor brain, 106
- peptide nucleic acid (PNA), 262, 264

- peptides, 60, 83, 91–92, 134–35,
 174–75, 198–99, 203, 238,
 262, 290, 292, 295, 297–98,
 320, 323
 11-amino-acid, 135
 12-amino-acid, 135
 19-amino-acid, 134
 29-amino-acid, 295
 amyloid, 94
 amyloid-beta, 20
 antennapedia, 83
 apolipoprotein E-3, 335
 β -amyloid, 173
 cationic, 83
 cell-penetrating, 83, 135, 172,
 177, 272
 cyclic RGD, 331
 fibrin-targeting, 203
 neuroprotective, 135
 parent, 295
 potent vasoconstrictive, 410,
 413
 purified RVG, 274
 shuttle, 328
 transferrin-mimetic, 19
 triglycine, 273
 vasoactive intestinal, 60
 pericytes, 12, 290, 323, 384, 386,
 393–94, 396–97
 permeability, 12, 43, 48, 89, 99,
 114, 134, 139, 162–63, 167,
 169, 174, 177, 391–94, 399
 diffusive, 440
 enhanced, 97, 319
 high, 23, 217
 higher endothelial, 13
 increased vascular, 24
 low, 162, 217
 low paracellular, 25
 nasal, 61
 passive, 10
 poor brain, 111
 vessel, 460
 permeation, 62, 99, 119, 163, 429
 nasal, 115
 PET, *see* positron emission
 tomography
 P-glycoprotein (P-gp), 10, 14–15,
 17–23, 107, 109–10, 112,
 119–21, 323, 394, 419
 P-gp, *see* P-glycoprotein
 pharmacodynamics, 49, 110, 132,
 387, 464
 pharmacokinetics, 12, 42, 49, 56,
 139, 235, 267, 354, 357, 367,
 373, 385, 387, 417, 464
 phosphorodiamidate morpholino
 oligomers (PMOs), 261–62,
 264
 photodynamic therapy, 326, 338
 photothermal therapy (PTT), 79,
 163, 194, 326, 329–30, 458
 physicochemical properties, 12,
 75, 116, 211, 217, 231, 322,
 429–30
 Plackett–Burman design, 376
 plasma, 12, 20, 42, 54, 57–58, 112,
 120, 200, 235–36, 238–39,
 265, 334, 367, 414
 plasmid DNA (pDNA), 126, 132,
 294, 301
 plasmonic nanoparticles, 161–62,
 317, 325–26, 331
 PLGA, *see* poly(lactic-co-glycolic
 acid)
 PMOs, *see* phosphorodiamidate
 morpholino oligomers
 PMs, *see* polymeric micelles
 PNA, *see* peptide nucleic acid
 PNPs, *see* polymeric nanoparticles
 polar surface area (PSA), 435
 polyamidoamine (PAMAM), 122,
 131, 133, 135, 294, 297, 300,
 416
 polydispersity index (PDI),
 108–10, 112–14, 119–20, 230,
 234–35, 239

- polyethylene glycol (PEG), 80–81, 122, 124, 135, 194, 170, 176, 194–95, 199, 271–73, 275, 292, 294, 301, 328–29, 332, 334, 414
- polyethylenimine (PEI), 176, 195, 292, 297, 301, 328
- poly(lactic-*co*-glycolic acid) (PLGA), 116, 127, 135, 138, 194, 296–97, 329, 444
- polymeric micelles (PMs), 62, 86, 125–27, 135, 202, 356
- polymeric monomers, 134
- polymeric nanoparticles (PNPs), 4, 81, 86, 89, 103, 116, 128–30, 135, 162, 356, 439, 459–60, 463
 - drug-loaded, 173
- polymers, 81, 86, 97, 100, 102, 138, 191, 212, 228–30, 328, 334, 365, 444
 - amphiphilic, 171
 - biosafe, 122
 - cationic, 292, 328
 - mucoadhesive, 114
 - mucopenetrating, 81
 - natural, 116
 - popular, 116
 - responsive, 86
 - semisynthetic, 116
 - sterically stabilising, 212
 - stimulus-responsive, 102
 - synthetic, 320
- polymersomes (POs), 100–102, 123–24, 135
- polymorphs, 230–32, 235
- porosity, 439
 - interstitium, 440
- POs, *see* polymersomes
- positron emission tomography (PET), 49, 194, 196, 321–22, 327, 329, 363, 417, 459
- PPs, *see* process parameters
- Prandtl equation, 219
- primary tumours, 391, 393, 460
- process parameters (PPs), 352–53, 364–66, 370–73, 375
 - critical, 353
- proteins, 4, 18, 91–92, 94–95, 99, 135, 260, 263–64, 270, 274, 294–95, 323, 330–31, 333–34, 385–86
 - acidic, 22
 - adherens junction, 396
 - aggregated, 122
 - amyloid, 198
 - amyloid precursor, 410–11
 - anti-insulin-like-growth-factor binding, 195
 - apoptotic, 124
 - basic, 105
 - breast cancer resistance, 10, 14
 - cellular, 333
 - effector, 135
 - heat shock, 333
 - human immunodeficiency virus Tat, 135
 - key PD, 201
 - membrane, 5
 - misfolded, 265
 - multidrug resistance-associated, 14
 - mutant Htt, 268
 - mutated, 428
 - pathogenic, 265
 - poorly folded, 197
 - positively charged, 108
 - presenilin, 410–11
 - receptor-related, 332
 - serum, 4, 267, 292
 - tau, 198, 410–11
 - tight junction, 391, 396, 460
 - toxic Huntingtin, 300
 - transmembrane, 267, 396
- PSA, *see* polar surface area
- PTT, *see* photothermal therapy 326, 329–30

- QbD, *see* quality-by-design
- QDs, *see* quantum dots
- QTPP, *see* quality target product profile
- quality-by-design (QbD), 351–53, 371, 375–78
- quality target product profile (QTPP), 353–56, 375–76
- quantum dots (QDs), 195–96, 199, 202, 431, 460
- quercetin, 93–94, 96, 111, 199, 336
- rabies virus glycoprotein (RVG), 175, 273, 276, 295, 299
- radioligands, attaching, 56
- radiotherapy, 167, 300, 330–31, 414–15, 460
- rapid clearance, 4, 43, 291, 458
- rapid expansion of supercritical solution (RESS), 221–22, 225–26
- reactive oxygen species (ROS), 95–96, 198, 326, 332
- receptor-mediated transcytosis (RMT), 14, 82–83, 92, 96–98, 107, 119–20, 123–25, 127–29, 131–32, 134, 172–73, 272, 290–91, 294, 323
- receptor-mediated transmigration, 335
- receptors, 14, 20, 82–84, 265, 272, 290, 295, 301–2, 323–24, 385, 393, 396, 428, 430, 432
- biological, 443
- endogenous, 204
- endothelial cell, 103
- galactose, 267
- glucose, 84
- hTfR, 393
- insulin, 237
- integrin, 301
- laminin, 295
- leptin, 295
- lipoprotein, 267
- low-density lipoprotein, 135, 237
- low-density lipoprotein BBB, 238
- mannose, 96
- membrane, 265
- membrane transport, 431
- nicotinic acetylcholine, 175, 295
- overexpressed, 4, 97
- proangiogenic apelin, 301
- selective oestrogen, 107
- targeted, 172
- type II, 324
- release, 4, 24, 77, 86, 93–94, 98, 101, 104–7, 263, 333, 337, 358, 367, 374, 445
- cargo, 291
- controlled, 61, 86, 103, 194, 204, 459
- drug product quality control, 365
- enhanced, 337
- extended, 237
- REM, *see* risk estimation matrix
- reproducibility, 52, 86–87, 102, 104, 140, 223–24, 275, 303, 338, 386, 389, 412
- residence time, 49, 62, 81, 114–15, 235, 276
- resistance, 260, 319, 388, 399–400
- multidrug, 14, 107
- RESS, *see* rapid expansion of supercritical solution
- retention, 97, 115, 319, 329, 358, 364, 461
- RISC, *see* RNA-induced silencing complex
- risk assessment, 355, 373–75, 465
- risk estimation matrix (REM), 371–74
- risks, 20, 137, 166, 259, 352, 372–73, 376, 396, 419, 464–65

- RMT, *see* receptor-mediated transcytosis
- RNA, 201, 258, 261–65, 291, 328
 hairpin, 263
 messenger, 295
 nuclear, 261
- RNAi, *see* RNA interference
- RNA-induced silencing complex (RISC), 263–64, 267
- RNA interference (RNAi), 259, 262–63, 266, 291, 300, 303
- ROS, *see* reactive oxygen species
- routes, 5, 43–45, 55, 57, 79–81, 83–84, 109–13, 115, 118, 123–34, 137, 171, 199, 239, 259
- carotid, 333
- chemical, 267
- conventional, 61
- direct, 59
- effective, 118
- intracarotid, 98
- intracellular axonal, 44
- intracranial, 290
- intravenous, 41–42, 58, 333
- metabolism, 417
- multiple, 259
- nasal, 41, 47, 356, 361
- nerve olfactory, 57
- new, 56
- non-invasive, 239
- olfactory intraneural, 46
- oral, 232
- parenteral delivery, 57
- possible, 16, 44
- preferential, 83
- synthetic, 162
- systemic, 82
- valid, 45
- RVG, *see* rabies virus glycoprotein
- safety, 4, 79, 196, 205, 289, 291, 352, 355, 357, 362, 364–65, 370, 378, 454–56, 462–66
- environmental, 464
- patient, 361, 368
- saturation solubility, 211, 217–19, 230–32
- scaffolds, 389, 391
- SDEDDS, *see* self-double-emulsifying drug delivery systems
- SDR, *see* static dephasing regime
- SELEX, *see* systematic evolution of ligands by exponential enrichment
- self-double-emulsion drug delivery systems (SDEDDS), 78, 117
- SERS, *see* surface-enhanced Raman spectroscopy
- shear stress, 385–86, 388–89, 394–95, 398–400
- side effects, 24, 94, 106, 218, 238, 299, 303, 319, 334, 338, 430
- cholinergic, 106
- dose-dependent, 319
- long-term, 140
- lower, 194
- minimal, 290, 304
- peripheral, 40, 43, 192
- systemic, 434
- unexpected, 338
- silencing, 19, 264, 268–70, 300
- single-photon emission computed tomography (SPECT), 321, 416–17
- single-stranded DNA (ssDNA), 260, 264
- single-stranded RNA (ssRNA), 264, 266
- siRNA, *see* small interfering RNA
- anti-Huntingtin, 299
- antisense, 263
- chemically modified, 268, 274
- chol-conjugated, 268
- chol-modified, 268
- double-stranded, 266
- naked, 267

- non-encapsulated, 118
- siRNA delivery, 268, 270, 300–301
- SLNs, *see* solid lipid nanoparticles
- small interfering RNA (siRNA),
 - 118, 133, 263, 265–69,
 - 272–76, 291–92, 295–97,
 - 299–301, 328
- small unilamellar vesicles (SUVs),
 - 88–89, 371
- SMD, *see* steered molecular dynamics
- SMLs, *see* solid magnetoliposomes
- SNALPs, *see* stable nucleic acid lipid particles
- solid magnetoliposomes (SMLs),
 - 335–36
- solid lipid nanoparticles (SLNs),
 - 78, 85, 103–11, 136, 274–76,
 - 356, 371–72
- solid lipids, 103, 106, 108, 110–15,
 - 275, 431
 - biocompatible, 105
- solvents, 138, 360, 368
 - organic, 171, 225, 228, 360
 - residual, 355, 360, 368, 377
- sonoporation, 290, 299, 304
- SPECT, *see* single-photon emission computed tomography
- SPIONs, *see* superparamagnetic iron oxide nanoparticles
 - polymer-coated, 177–78
 - ultrasmall, 335
- SPMNs, *see* superparamagnetic nanoparticles
- SPR, *see* surface plasmon resonance
- ssDNA, *see* single-stranded DNA
- ssRNA, *see* single-stranded RNA
- stabilisers, 113, 115, 211, 220,
 - 224–25, 229–30, 234–35,
 - 237–40
- best, 230
- ionic, 230
- nanocrystal, 212
- toxic, 170
- stability, 4, 86–87, 89, 101–2, 111,
 - 114, 229, 231, 234, 336, 338,
 - 356–57, 360–62, 443, 445
- drug, 319
- high physicochemical, 104
- liposomal, 89
- long-term, 103, 138
- long-term physicochemical, 104,
 - 357
- superior, 101
- thermodynamic, 117, 231
- stable nucleic acid lipid particles (SNALPs), 272–73
- static dephasing regime (SDR), 322
- steered molecular dynamics (SMD), 433
- stem cells, 5, 12, 140, 299, 394
- stroke, 40, 202–4, 238, 408, 410,
 - 412–13, 416, 457
- acute, 419
- embolic, 203
- ischaemic, 22, 384, 408–9, 412
- supercritical solutions, 221–22,
 - 225, 227
- superparamagnetic iron oxide nanoparticles (SPIONs),
 - 166–67, 172, 176–77, 334–35
- superparamagnetic nanoparticles (SPMNs), 433
- support vector machine (SVM),
 - 435, 437
- surface charge, 98, 109–10, 115,
 - 234, 272, 358, 364, 430, 441
- surface chemistry, 4, 432
- surface-enhanced Raman spectroscopy (SERS), 198, 201,
 - 327
- surface functionalisation, 77, 104,
 - 165, 172, 177, 319, 324, 458
- surface plasmon resonance (SPR),
 - 163, 324–25
- surface-to-volume ratio, high, 77,
 - 324

- surfactants, 82, 86–87, 105–6, 108, 110–13, 115–20, 136, 169–71, 212, 225, 227
- biocompatible, 118
- hydrophilic non-ionic, 119, 176
- ionic, 229
- non-ionic, 116, 273
- non-ionic amphiphilic, 230
- serine-derived, 432
- sterically impeding, 136
- survival, 94, 99, 125, 127–28, 134, 175, 177, 199, 204, 238, 297, 300–301, 319, 391, 459–61
- sustained release, 110, 120, 237, 240, 275
- SUVs, *see* small unilamellar vesicles
- SVM, *see* support vector machine
- symptoms, 106, 189, 197, 268, 300, 411, 415, 460–61
- systematic evolution of ligands by exponential enrichment (SELEX), 265
- systemic clearance, 138, 319
- systemic exposure, 39–40, 42, 48
- target cells, 292, 414, 458
- targeting, 80, 84, 91, 94, 96–98, 303, 323
- targeting agents, 120, 204, 331, 430
- targeting therapy, 194, 200
- target mRNA, 260, 263
- target tissues, 77, 82, 90, 101
- TEER, *see* transepithelial electrical resistance
- Tf, *see* transferrin
- TfRs, *see* transferrin receptors
- theranostic agents, 318, 320–21, 323–24
 - flexible, 330
 - magnetic-based multifunctional, 324
 - potential, 203
 - theranostics, 93, 189, 202, 320, 339, 417
 - therapeutic action, effective, 321
 - therapeutic activity, 259
 - therapeutic agents, 42, 44, 46, 75–76, 93, 95, 97, 101, 103–5, 107, 111–14, 118, 120, 290, 321
 - therapeutic alternatives, 4, 190, 205, 430
 - therapeutic approaches, 61, 97, 265, 300, 303, 326, 408
 - therapeutic effects, 53, 95, 419
 - enhanced, 334
 - therapeutic efficacy, 40, 48, 77, 95, 105, 112, 194, 196, 239, 276, 416, 419, 427
 - therapeutic genes, 4, 290, 299, 301, 303
 - therapeutic ODNs, 266, 276
 - therapeutics, 4, 40, 42, 44, 107, 109, 111, 260, 265, 290, 292, 299, 301, 427, 431
 - advanced, 259
 - circulating, 81
 - delivery of, 41, 61, 77, 105, 189, 195, 290, 300, 429
 - miRNA-based, 264
 - new effective, 204
 - nucleic acid, 303
 - transport of, 77, 105, 427
 - therapeutic target, 10, 79, 274
 - therapy, 93–94, 111, 129, 131, 163, 258, 301, 319–20, 394, 409, 415, 438, 459
 - adjunctive, 416
 - adjuvant, 317
 - current, 197
 - effective, 189
 - enhanced targeted, 190, 204
 - failed conventional, 417
 - genetic, 97, 99
 - guided-thrombolytic, 203
 - human, 414

- individualised, 303
- iron-chelating, 24
- long-term, 336
- low-dose, 110
- new approval, 409
- novel, 390, 408, 414
- optimised, 430
- photothermal, 162
- photodynamic, 326, 338
- potential, 408
- preischaemic, 96
- sustainable, 430
- synergistic, 319
- toxoplasmic encephalitis, 234
- validated, 11
- thermogravimetry, 232
- tight junctions, 10, 13, 22, 24, 104, 108, 178, 299–300, 323, 394, 398–99, 432, 460
- TNF- α , *see* tumour necrosis factor alpha
- toxic effects, 77, 109, 119, 137, 301
- toxicity, 19, 40, 48, 77–79, 85–87, 121–22, 130, 135–38, 267, 274, 414–15, 417, 454–55, 460, 462
- A β -induced, 94
- cell, 98
- drug-induced, 234
- haemolytic, 138
- increased, 49
- inducing, 275
- local, 319
- low, 85, 163, 165, 324
- minimal, 138
- nanocarrier, 429
- neuronal, 269
- possible, 204
- potential, 136, 273
- relative, 204
- significant, 138, 461
- systemic, 24, 105, 137
- unexpected, 19
- toxins, 463
- environmental, 410–11
- transcytosis, 13–14, 103–4, 109, 294, 439, 463
 - adsorptive-mediated, 14, 82, 290, 297
 - carrier-mediated, 82
 - efficient BBB, 172
 - receptor-mediated, 14, 82, 172–73, 272, 323
 - strong, 172
- transdermal administration, 80, 100
- transepithelial electrical resistance (TEER), 385, 389–91, 394–95, 398–400
- transfection, 90, 118, 126, 271, 273, 303
- transferrin (Tf), 83, 123, 135, 172, 272, 294–95, 300, 323–24, 327, 335, 416
 - anti-human, 393
- transferrin receptors (TfRs), 83, 172, 174, 237, 294–97, 324, 327–28, 393
 - peptide-binding, 276
- translational medicine, 453–57
- transporters, 17–19, 84, 298, 385, 393, 396
 - anionic amino acid, 84
 - ATP-binding cassette, 323
 - beta amino acid, 84
 - carrier-mediated, 298
 - cationic amino acid, 84
 - choline, 84
 - multidrug-resistant, 399
 - neutral amino acid, 84
 - organic anion, 270
- transport routes, 79, 82–83
 - direct, 47
 - endogenous BBB, 77
 - inward, 25
- Transwell BBB models, 386
- Transwell cultures, 384, 387
- Transwell models, 386, 388

- treatment, 92–93, 110, 112–13, 189–92, 197–99, 201–4, 258–61, 289–91, 398, 407, 415–17, 419, 440–43, 454–55, 458–59
 - aggressive, 300
 - brain tumour, 99
 - cancer, 113, 162
 - chronic, 62
 - disease-modifying, 105
 - effective, 204, 352
 - glioblastoma, 333, 434
 - glioblastoma multiforme, 432
 - hydrothermal, 170
 - long-term, 232
 - oral, 95
 - postischaemic, 96
 - promising, 456
 - radiation, 334
 - single- or multiple-drug, 412
 - standard, 459
 - tPA, 419
- triblock copolymers, 62, 100–101, 134
- trigeminal nerve pathways, 45–46, 60
- triglycerides, 117, 136
 - caprylic/capric, 103, 114–15
 - short-chain fatty acid, 136
 - solid, 276
- tumour cells, 196, 238, 265–66, 272, 323, 325–26, 328, 330–31, 393, 414, 461
- tumour growth, 110, 125, 272, 297, 301, 407, 418, 429, 438–39
- tumour necrosis factor alpha (TNF- α), 21, 93
- tumour progression, 266, 301, 443, 459, 461
- tumours, 97, 193–96, 238–39, 264–66, 271–72, 275–76, 318–19, 326–30, 391, 398, 412, 414, 418–19, 438–41, 460–61
 - malignant, 460
 - solid, 440, 459
- Turkevich method, 169–70
- ultrasmall particles of iron oxide (USPIO), 203
- ultrasonication, 117, 371
- ultrasound, 5, 97, 299, 417, 440, 459
- United States Food and Drug Administration (USFDA), 212, 258, 291, 303, 333
- United States Pharmacopeia (USP), 355, 365–69
- upregulation, 20, 23, 258
- uptake, 17, 44, 99, 114–15, 119, 132, 162, 267, 292, 294, 303, 327, 364, 440
 - cellular, 4, 89, 108, 123, 260, 427
 - endocytic, 109
 - enhanced nanovector, 196
 - gymnotic, 266
 - higher, 23, 328
 - higher glucose, 322
 - high tumour, 196
 - interstitial, 440
 - intracellular, 232
 - intracellular axonal, 44
 - lower, 23
 - neuronal, 44
 - phagocytotic, 237
 - postinjection tumour, 329
 - reticuloendothelial system, 275
 - selective, 268
 - selectivity, 107
 - strong, 98
- USFDA, *see* United States Food and Drug Administration
- USP, *see* United States Pharmacopeia
- USPIO, *see* ultrasmall particles of iron oxide
- van der Waals interactions, 84, 236

- vascular endothelial growth factor receptor (VEGFR), 323, 391
- vasoactive intestinal peptide (VIP), 60
- VEGFR, *see* vascular endothelial growth factor receptor
- velocity, 167
 - high, 228
 - relative, 220
- ventricles, 13, 15
 - cerebral, 13
 - lateral, 55
- vesicles, 14, 88–89, 91, 93, 95, 97, 99, 101–2, 329, 373, 377
 - caveole, 13
 - cytoplasmic, 14
 - endocytic, 174
 - extracellular, 5, 274
 - multilamellar, 88, 371
 - natural, 274
 - oxide-loaded ultrasmall
 - plasmonic gold nanorod, 194
 - self-assembled, 100
 - spherical, 270
- viability, 45, 456
 - commercial, 357
 - high, 107
- VIP, *see* vasoactive intestinal peptide
- viral vectors, 259, 289, 291, 303
- viscosity, 61, 120, 167, 330, 355, 361, 368
- visit-limited regime (VLR), 322
- VLR, *see* visit-limited regime
- WGA, *see* wheat germ agglutinin
- wheat germ agglutinin (WGA), 44, 174
- xenobiotics, 17, 81
 - X-ray CT, 338, 417
 - X-ray powder diffraction, 232, 235
- zeta potential, 105–6, 108, 110, 113, 120, 229, 321, 354, 364
 - average, 112, 114, 119

“Written by experts from academia and industry, with a multidisciplinary and instructive orientation, this is an authoritative book which may propel the application of nanomedicine to the diagnosis, therapy and monitoring of brain diseases.”

Prof. Carmen Alvarez-Lorenzo
University of Santiago de Compostela, Spain

“This book provides a perspective on nanotechnology solutions for delivery of therapeutics to the brain. It will serve as an excellent reference for investigators who are interested in finding solutions for treatment of central nervous system diseases.”

Prof. Mansoor M. Amiji
Northeastern University, Boston, USA

In an era wherein nanotechnology has sparked a huge research interest, brain drug delivery is not an exception. Aimed at fighting several central nervous system (CNS) conditions, tailored nanoparticles open new avenues to address several challenges in the fields of brain drug delivery and targeting. With contributions from experts in different, complementary fields, this book covers a diversity of nanomedicines applied in the treatment and/or diagnosis and monitoring of CNS disorders, as well as aspects concerning their translation from bench to clinical practice. It encompasses general aspects pertaining to fundamental development, including tripartite in silico–in vitro–in vivo approaches. The book will inspire readers to discover possible approaches to holistically delivering drugs into the brain and will appeal to anyone involved in nanomedicine, pharmaceuticals, neurological and cancer therapies, drug delivery research and computational and regulatory sciences.



Carla Vitorino is invited assistant professor at the Faculty of Pharmacy, University of Coimbra, Portugal, since 2014. She graduated in pharmaceutical sciences in 2007 and obtained her PhD in pharmaceuticals in 2013 from the University of Coimbra. She has been working on the application of nanotechnology to drug permeation enhancement strategies for transdermal, oral and drug delivery systems for brain targeting and has published several scientific papers in peer-reviewed, high-impact journals, bringing together her vast experience in pharmaceutical technology, especially in the areas of nanotechnology and regulatory science. Her main research interests are nanotechnology, controlled release and the development of new drug delivery systems with a quality-by-design perspective.



Andreia Jorge obtained her PhD in macromolecular chemistry in 2013 from the University of Coimbra. During her PhD, she worked at the Faculty of Pharmacy, University of Barcelona, Spain, and the Faculty of Chemistry and Pharmacy, University of Ludwig-Maximilians, Germany. She then moved to a postdoctoral fellow position in a joint project with the Coimbra Chemistry Centre and the Institute of Advanced Chemistry of Catalonia, Spain, where she researched the chemical modification of oligonucleotides with therapeutic applications, using both experimental and computational approaches. Her current research interests include chemical-modified therapeutic oligonucleotides (antisense and siRNA) for gene silencing, antiproliferative oligonucleotides, sequence-specific protein–DNA interactions, lipid- and polymer-based drug delivery systems and programmable self-assembling DNA nanostructures.



Alberto Pais is full professor of chemistry and head of the Department of Chemistry, University of Coimbra. He is also head of the Macromolecular, Colloids and Photochemistry Group, Coimbra Chemical Center (in collaboration with the Multicomponent Systems lab, a part of that group). He has published 14 book chapters, 2 books and 200 articles in international peer-reviewed journals. His scientific interests are vast and include chemometrics, pharmaceutical technology, molecular modelling/simulation and data science.



JENNY STANFORD
PUBLISHING

V789
ISBN 978-981-4877-31-2



9 789814 877312